Previous 10 | Next 10 |
home / stock / bayry / bayry news
ESSA Pharma developed a novel mode of action drug, EPI-7386, for the treatment of metastatic castrate-resistant prostate cancer. Pre-clinical and early Ph 1 results are promising. ESSA's share price crashed in mid-Aug when a change in the Ph 1 trial protocol was announced, and a delay...
Investing in Bayer isn't for the faint-hearted given the company's recent and likely future valuation and earnings volatility. However, beneath the hood there's a qualitative company with superb fundamentals and an excellent portfolio. At a certain valuation, this cannot be anythi...
Bayer Aktiengesellschaft (BAYZF) Q3 2021 Earnings Conference Call Nov 09, 2021 08:00 AM ET Company Participants Oliver Maier - Head, Investor Relations Werner Baumann - Chief Executive Officer Wolfgang Nickl - Chief Financial Officer Stefan Oelrich - President, Pharmaceuticals Division Liam C...
The following slide deck was published by Bayer Aktiengesellschaft in conjunction with their 2021 Q3 earnings call. For further details see: Bayer Aktiengesellschaft 2021 Q3 - Results - Earnings Call Presentation
Bayer (OTCPK:BAYRY +1.2%) moves higher after Q3 EBITDA jumped 16% Y/Y to €2.09B (~$2.4B), topping an average analyst forecast of €1.94B, and revenues rose 15% to €9.78B. Bayer swung to a Q3 net profit of €85M from a €2.74B net loss a year earlier, when resul...
Cyclerion is a spinoff from Ironwood Pharmaceuticals that has had 2 clinical failures but has a unique lead asset in neurodegeneration. Cyclerion has upcoming phase 2 data coming out in H12022 that will be a major inflection point to potentially open up new opportunities for the distr...
CRISPR Therapeutics was down at one point 10% after hours following reports of poorer than expected efficacy levels for its CTX110 CAR-T cell therapy. CRISPR is currently (55%) off all-time highs set at the beginning of 2021. Being a leader in gene editing, this may be a good time...
Inflation concerns have started to affect market sentiment but it is highly uncertain if that will lead to a real market correction or just some short-term dips. I am continuing my monthly investment plans while still awaiting a market correction or possibly a real crash once market e...
I want to follow up on last quarter’s commentary about governance with a related topic that we get asked about: shareholders vs. stakeholders. Is it really one against the other? Today, some CEOs are again following this playbook. Slicing R&D expenditures at drug companies ...
Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analy...
News, Short Squeeze, Breakout and More Instantly...
Bayer AG ADR Company Name:
BAYRY Stock Symbol:
OTCMKTS Market:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...